Here is Why Sutro Biopharma (STRO) is One of the Tiny Stocks That Are On Fire Right Now

Sutro Biopharma Inc. (NASDAQ:STRO) is one of the tiny stocks that are on fire right now. On March 23, Sutro Biopharma reported its full-year 2025 financial results, highlighting a strengthened balance sheet and significant clinical milestones for its antibody-drug conjugate/ADC platform. The company ended 2025 with $141.4 million in cash and marketable securities, which, when combined with a recent $110 million capital raise, extends its cash runway into at least Q2 2028. This financial stability supports a sharpened focus on advancing both wholly owned and partnered oncology programs.

A major focus for 2026 is the progress of Sutro’s internal pipeline. The company completed dosing for the third cohort in its Phase 1 trial of STRO-004, a potential best-in-class Tissue Factor/TF ADC, with initial clinical data expected in mid-2026. Additionally, Sutro Biopharma Inc. (NASDAQ:STRO) is accelerating the development of STRO-227, its first wholly owned dual-payload program targeting PTK7, with an IND submission now targeted for 2026. The company also expects its ITGB6-targeting ADC, STRO-006, to enter clinical development this year.

Here is Why Sutro Biopharma (STRO) is One of the Tiny Stocks That Are On Fire Right Now

Africa Studio/Shutterstock.com

Sutro’s collaboration with Astellas Pharma has also reached a key inflection point, with their first partnered dual-payload immunostimulatory ADC entering the clinic. Patient dosing is currently in Q2 2026. A second partnered program also advanced into IND-enabling toxicology studies late last year, further validating Sutro’s site-specific ADC platform through strategic partnerships.

Sutro Biopharma Inc. (NASDAQ:STRO) is a clinical-stage biotechnology company using a proprietary cell-free platform to develop next-gen antibody-drug conjugates/ADCs for cancer. By optimizing antibodies, linkers, and single or dual-payloads, the company aims to improve drug exposure and overcome treatment resistance in oncology markets with significant unmet needs.

While we acknowledge the risk and potential of STRO as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than STRO and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: 33 Stocks That Should Double in 3 Years and Cathie Wood 2026 Portfolio: 10 Best Stocks to Buy. 

Disclosure: None. Follow Insider Monkey on Google News.